Nemaura Medical announced that on February 23, 2023, the company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that the company was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022. Subsequently, on February 24, 2023, the company filed the Form 10-Q and regained compliance with Nasdaq Rule 5250(c)(1). On February 27, 2023, the Company received a notice from Nasdaq that, based on the Form 10-Q filing on February 24, 2023, Nasdaq determined that the company was in compliance with Nasdaq Rule 5250(c)(1) and the matter was closed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical Announces Receipt of Notice from Nasdaq
- Nemaura Medical price target lowered to $7 from $8 at H.C. Wainwright
- Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
- Nemaura Medical reports Q3 EPS (7c), consensus (18c)
- Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference